Ipratropium Bromide And Albuterol Sulfate Solution
Product Images NDC 68788-8103

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Ipratropium Bromide And Albuterol Sulfate (NDC 68788-8103). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ipratropium Bromide 05mg And Albuterol Sulfate 3mg Inh Sol. (66f32a06 C880 4b5b 837b 951e1e01e040 00)

Label for Ipratropium Bromide 0.5mg and Albuterol Sulfate 3mg Inhalation Solution, generic for Duoneb. The label indicates a 3mL unit-dose vial containing 0.5mg ipratropium bromide and 3mg albuterol sulfate. The labeler is Preferred Pharmaceuticals Inc., with manufacturing by Nephron SC Inc. It includes warnings about use, storage, and legal cautions. The label also includes directions in English and Spanish referencing box instructions.*

FDA Label Image

B5387e98-figure-01 (B5387e98 Figure 01)

Chemical structure diagram of Ipratropium Bromide and Albuterol Sulfate shown as a molecular formula with functional groups and bonds, including a benzene ring, hydroxyl groups, and a tetrahedral nitrogen moiety.*

FDA Label Image

B5387e98-figure-02 (B5387e98 Figure 02)

Chemical structure of ipratropium bromide, showing the molecular arrangement including a quaternary ammonium group and a benzene ring, along with the bromide hydrate (Br- H2O) component.*

FDA Label Image

B5387e98-figure-03 (B5387e98 Figure 03)

A line graph showing the volume in liters on the y-axis and hours after dosing on the x-axis. It compares the respiratory effect over time of Albuterol, Ipratropium, and the combination of Ipratropium Bromide and Albuterol Sulfate inhalation, illustrating changes in lung function after administration.*

FDA Label Image

B5387e98-figure-04 (B5387e98 Figure 04)

A data table showing adverse events occurring in more than 1% of patients in at least one treatment group of Albuterol, Ipratropium, and the combination Ipratropium Bromide and Albuterol Sulfate. The table lists body systems and specific symptoms with counts and percentages of patients experiencing each adverse event within groups of around 750 patients per treatment.*

FDA Label Image

B5387e98-figure-05 (B5387e98 Figure 05)

An instructional diagram showing the preparation of Ipratropium Bromide and Albuterol Sulfate respiratory solution. The image depicts a hand holding an inhalation chamber, with the solution being drawn from a vial labeled with the drug name, indicating steps for inhalation administration.*

FDA Label Image

B5387e98-figure-06 (B5387e98 Figure 06)

An instructional diagram illustrating the assembly or connection of a respiratory inhalation solution device, showing a nozzle or mouthpiece being connected to a larger inhalation apparatus. The image likely corresponds to the use or setup of Ipratropium Bromide and Albuterol Sulfate solution for inhalation.*

FDA Label Image

B5387e98-figure-07 (B5387e98 Figure 07)

An instructional illustration showing a person using a respiratory inhalation device with a mouthpiece, demonstrating how to properly inhale the medication. The person holds the inhaler device close to their mouth and appears to be administering the medication through inhalation.*

FDA Label Image

B5387e98-figure-08 (B5387e98 Figure 08)

Illustration showing a person using a respiratory inhalation device by placing the mouthpiece in their mouth and pressing down on the attached spray pump, demonstrating the proper technique for administering a solution inhalation dose.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.